<?xml version="1.0" encoding="UTF-8" ?> 
	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.google.com/schemas/sitemap/0.84 http://www.google.com/schemas/sitemap/0.84/sitemap.xsd">
   <!--  HOMEPAGE  --> 
   <url>
    <loc>http://www.syntaxin.com/</loc>
    <changefreq>monthly</changefreq>
	<priority>1.0</priority>
   </url>  
   
      <!--  PRODUCT PIPELINE  --> 
   <url>
    <loc>http://www.syntaxin.com/biopharmaceutical-product-pipeline.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.8</priority>
   </url> 
   
   <!--  RESPIRATORY THERAPEUTICS  --> 
   <url>
    <loc>http://www.syntaxin.com/respiratory-diseases-treatment.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.6</priority>
   </url> 
   
   <!--  SOOTHING CHRONIC PAIN  --> 
   <url>
    <loc>http://www.syntaxin.com/soothing-chronic-pain.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.6</priority>
   </url> 
   
      <!--  TREATING ENDOCRINE DISORDERS  --> 
   <url>
    <loc>http://www.syntaxin.com/treating-endocrine-disorders.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.6</priority>
   </url> 
   
     <!--  TREATING OBESITY AND METABOLIC DISORDERS  --> 
   <url>
    <loc>http://www.syntaxin.com/treating-obesity.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.6</priority>
   </url> 
   
      <!--  RESEARCH AND DEVELOPMENT  --> 
   <url>
    <loc>http://www.syntaxin.com/biotech-research-development.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.8</priority>
   </url> 
   
   <!--  INHIBITION OF CELL SECRETION  --> 
   <url>
    <loc>http://www.syntaxin.com/cell-secretion-inhibition.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.6</priority>
   </url> 
   
    <!--  CREATING NOVEL RECOMBINANT PROTEINS  --> 
   <url>
    <loc>http://www.syntaxin.com/creating-novel-proteins.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.6</priority>
   </url> 
   
     <!--  THERAPEUTIC POTENTIAL OF SYNTAXINS BIOTECHNOLOGY  --> 
   <url>
    <loc>http://www.syntaxin.com/therapeutic-potential.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.6</priority>
   </url> 
   
       <!--  ABOUT SYNTAXIN BIOTECHNOLOGY  --> 
   <url>
    <loc>http://www.syntaxin.com/about-syntaxin.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.4</priority>
   </url> 
   
       <!--  SYNTAXINS HISTORY TIMELINE  --> 
   <url>
    <loc>http://www.syntaxin.com/history-timeline.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.4</priority>
   </url> 
   
       <!--  BIOTECHNOLOGY BOARD OF DIRECTORS --> 
   <url>
    <loc>http://www.syntaxin.com/about-directors.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.4</priority>
   </url> 
   
          <!--  BIOPHARMACEUTICALS MANAGEMENT TEAM --> 
   <url>
    <loc>http://www.syntaxin.com/about-management-team.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.4</priority>
   </url> 
   
             <!--  BIOTECH INVESTORS --> 
   <url>
    <loc>http://www.syntaxin.com/biotech-investors.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.4</priority>
   </url> 
   
                <!--  SCIENTIFIC ADVISORY BOARD --> 
   <url>
    <loc>http://www.syntaxin.com/scientific-advisory-board.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.4</priority>
   </url> 
   
                <!--  CONTACT SYNTAXIN --> 
   <url>
    <loc>http://www.syntaxin.com/contact-biopharmaceutical-firm.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.4</priority>
   </url> 
   
                   <!--  LONDON DIRECTIONS --> 
   <url>
    <loc>http://www.syntaxin.com/london-biopharma.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.2</priority>
   </url> 
   
                      <!--  BRISTOL DIRECTIONS --> 
   <url>
    <loc>http://www.syntaxin.com/bristol-biopharma.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.2</priority>
   </url> 
   
                        <!--  MANCHESTER DIRECTIONS --> 
   <url>
    <loc>http://www.syntaxin.com/manchester-biopharma.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.2</priority>
   </url> 
   
                           <!--  LIVERPOOL DIRECTIONS --> 
   <url>
    <loc>http://www.syntaxin.com/liverpool-biopharma.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.2</priority>
   </url> 
   
                              <!--  BIRMINGHAM DIRECTIONS --> 
   <url>
    <loc>http://www.syntaxin.com/birmingham-biopharma.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.2</priority>
   </url> 
   
                                 <!--  BIRMINGHAM DIRECTIONS --> 
   <url>
    <loc>http://www.syntaxin.com/birmingham-biopharma.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.2</priority>
   </url>                              
   
    <!--  LUTON DIRECTIONS --> 
   <url>
    <loc>http://www.syntaxin.com/luton-biopharma.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.2</priority>
   </url> 
   
   <!--  COPYRIGHT NOTICE --> 
   <url>
    <loc>http://www.syntaxin.com/copyright-syntaxin.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.1</priority>
   </url>
   
    <!--  ACCESSIBILITY NOTICE --> 
   <url>
    <loc>http://www.syntaxin.com/accessibility.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.1</priority>
   </url>
   
    <!--  SITEMAP --> 
   <url>
    <loc>http://www.syntaxin.com/sitemap.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.1</priority>
   </url>
   
      <!--  BIOTECH NEWS AND PRESS --> 
   <url>
    <loc>http://www.syntaxin.com/bio-tech-news.php</loc>
    <changefreq>monthly</changefreq>
	<priority>0.8</priority>
   </url>
   
   <!--  BIOTECH FUTURE EVENTS --> 
   <url>
    <loc>http://www.syntaxin.com/bio-tech-news.php?ev=f</loc>
    <changefreq>monthly</changefreq>
	<priority>0.8</priority>
   </url>
   
      <!--  SYNTAXIN LAUNCH SITE --> 
   <url>
    <loc>http://www.syntaxin.com/biopharma-news-article.php?id=1</loc>
    <changefreq>monthly</changefreq>
	<priority>0.4</priority>
   </url>
   
       <!--  SYNTAXIN GET B SERIES FUNDING --> 
   <url>
    <loc>http://www.syntaxin.com/biopharma-news-article.php?id=39</loc>
    <changefreq>monthly</changefreq>
	<priority>0.4</priority>
   </url>
   
   <!--  SYNTAXIN APPOINT PHIL BOYD AS CFO --> 
   <url>
    <loc>http://www.syntaxin.com/biopharma-news-article.php?id=4</loc>
    <changefreq>monthly</changefreq>
	<priority>0.4</priority>
   </url>
   
      <!--  SYNTAXIN WORK WITH ALLERGAN --> 
   <url>
    <loc>http://www.syntaxin.com/biopharma-news-article.php?id=6</loc>
    <changefreq>monthly</changefreq>
	<priority>0.4</priority>
   </url>
   
        <!--  SYNTAXIN APPOINT PATRICK DOYLE AS CEO --> 
   <url>
    <loc>http://www.syntaxin.com/biopharma-news-article.php?id=7</loc>
    <changefreq>monthly</changefreq>
	<priority>0.4</priority>
   </url>
   
      <!--  SYNTAXIN RECEIVES COLLABORATIVE DTI GRANT --> 
   <url>
    <loc>http://www.syntaxin.com/biopharma-news-article.php?id=8</loc>
    <changefreq>monthly</changefreq>
	<priority>0.4</priority>
   </url>
   
       <!--  SYNTAXIN LTD LAUNCHED --> 
   <url>
    <loc>http://www.syntaxin.com/biopharma-news-article.php?id=9</loc>
    <changefreq>monthly</changefreq>
	<priority>0.4</priority>
   </url>


  </urlset> 